Axicabtagene ciloleucel

From Ganfyd

(Redirected from KTE-C19)
Jump to: navigation, search
rINN: Axicabtagene ciloleucel
Other Names
KTE-C19, axi-cel ®
Pharmacological Information
Web information on Axicabtagene ciloleucel
NHS Evidence on Axicabtagene ciloleucel
DrugBank on Axicabtagene ciloleucel
Relevant Clinical Literature
Pubmed on Axicabtagene ciloleucel
RCT with Axicabtagene ciloleucel
Systematic reviews of Axicabtagene ciloleucel
Axicabtagene ciloleucel in N Eng J Med, Lancet, JAMA, BMJ
Axicabtagene ciloleucel in Cochrane Collaboration
TRIP Database on Axicabtagene ciloleucel
Google Scholar on Axicabtagene ciloleucel
Bandolier on Axicabtagene ciloleucel
UK Guidance
Nice Guidance on Axicabtagene ciloleucel

BNF-registration required
BNF for children-registration required

UK directory of medicines
UK Medicine Guide (eg pictures of capsules)
Centre for Reviews and Dissemination databases -DARE & NHS EED (evaluates reliability of research)
SNOMED search
Regulatory Literature
UK SPCs of medicines with marketing authorisation
EMEA search
FDA search
Other Literature
PubChem on Axicabtagene ciloleucel
ChemSpider on Axicabtagene ciloleucel
CTD (Comparative Toxicogenomics Database) link
ChemIndustry.com link
Protein Structural Information on Axicabtagene ciloleucel
Biological Information (GenomeNet)
Protein Knowledgebase (UniProtKB)
Please read pharmacological data limitations
Other Wikis
Wikipedia on Axicabtagene ciloleucel (Less technical, ? quality control)
Axicabtagene ciloleucel is chimeric antigen receptor T-cell immunotherapy (CAR-T cell therapy) preparation of autologous T cells genetically modified to express a chimeric antigen receptor (CAR) targeting CD19. The product is in development to treat adult patients with non-Hodgkin lymphoma (NHL), diffuse large B cell lymphoma (DLBCL)[1], primary mediastinal B-cell lymphoma (PMBCL), transformed follicular lymphoma (TFL)[2], chronic lymphocytic leukaemia and acute lymphoblastic leukaemia (ALL)[3]. It is a member of the EMEA's PRIority MEdicines (PRIME) scheme for breakthrough therapies. Licensing commenced in major markets 2017/18.

References

  1. ↑ Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiezorek J, Go WY. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. The New England journal of medicine. 2017 Dec; 377(26):2531-2544.(Print-Electronic) (Link to article – subscription may be required.)
  2. ↑ Kite Pharma, Inc Press release 28 Feb 2017
  3. ↑ Press release Kite Pharma 8 August 2017
Retrieved from "http://www.ganfyd.org/index.php?title=Axicabtagene_ciloleucel"